Myriad Genetics ($MYGN) is expanding its companion diagnostics partnership with AstraZeneca ($AZN), planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib). The move comes a few months after Salt Lake City, UT-based Myriad won FDA approval to use its BRACAnalysis test alongside Lynparza to screen for BRCA1 and BRCA2 mutations in women with ovarian cancer. "Our collaboration with AstraZeneca is a big step forward in the fight against pancreatic cancer and in ensuring that personalized medicine becomes a reality," Mark Capone, president of Myriad Genetic Laboratories, said in a statement. "BRCAnalysis CDx has the potential to quickly and accurately identify those patients who may be candidates for treatment with Lynparza and hopefully to accelerate better health outcomes." Statement | More